BioCentury | Jan 28, 2013
Company News

Cerep, Eurofins deal

...Eurofins began a tender offer to acquire Cerep for €2 per share, or about €25.3 million...
...deal was announced. Cerep's board unanimously approved the deal. The tender offer expires Feb. 27. Cerep...
...services for in vitro pharmacology, in vitro ADMET and in vivo pharmacokinetics for drug development. Cerep...
BioCentury | Apr 4, 2011
Finance

Eleventh Hour Push

...stabilizer in Phase III testing for Huntington's disease; expects to save $17.3M by 2012 1/18/11 Cerep...
BioCentury | Jan 24, 2011
Company News

Cerep admet, supply/service news

...company will close its office in Paris, France, and move its headquarters to Celle L'Evescault. Cerep...
...pharmacology, in vitro ADMET and in vivo pharmacokinetics for drug development. At June 30, 2010, Cerep...
...of €11.2 million ($13.7 million) and a six-month operating loss of €1.4 million ($1.7 million). Cerep...
BioCentury | Nov 1, 2010
Company News

Averion, Cerep deal

...to pay the interest on debt owed to Cerep stemming from Averion's 2007 acquisition of Cerep's...
...the debt are ongoing (see BioCentury, Nov. 5, 2007). Averion International Corp. (OTCBB:AVRO), Southborough, Mass. Cerep...
BioCentury | Jun 22, 2009
Company News

Cerep, Eli Lilly, Servier deal

...not disclosed. Separately, Cerep will screen Servier's compound library against targets identified by the pharma. Cerep...
...will be responsible for development and validation of pharmacological assays and profiling the compounds identified. Cerep...
...will receive an undisclosed monthly payment during the three-year deal. Further terms were not disclosed. Cerep...
BioCentury | Jan 12, 2009
Company News

Cerep, Laboratoires Thea deal

...exclusive, worldwide license to develop and commercialize Cerep's LFA-1 (CD11a-CD18) antagonist to treat ophthalmic disorders. Cerep...
...in animal models, which is expected to begin this half. The compound was discovered under Cerep's...
...to Cerep after hepatotoxicity was observed during Phase II testing for autoimmune and inflammatory diseases. Cerep...
BioCentury | Jan 8, 2009
Cover Story

Taking the inflammation out of epilepsy

...Inc. (NASDAQ:BIIB), Cambridge, Mass. BioInvent International AB (SSE:BINV), Lund, Sweden Biovitrum AB (SSE:BVT), Stockholm, Sweden Cerep...
...Corp. and Sunesis Pharmaceuticals Inc. , which have SAR1118 in Phase I testing for conjunctivitis. Cerep...
BioCentury | Dec 15, 2008
Company News

Cerep, sanofi-aventis deal

...payment to Cerep and reimbursement of certain Cerep's expenses. Cerep also is eligible for royalties. Cerep...
BioCentury | Jun 2, 2008
Finance

Next BioTech

...€199.3 Amsterdam Molecular (Euronext:AMT) €102.1 Bioalliance (Euronext:BIO) €88.1 Biotech (Pricaf) (Euronext:BIOT) €19.3 Cellectis (Euronext:ALCLS) €66.0 Cerep...
BioCentury | May 19, 2008
Company News

Sepal Pharma management update

...Sepal Pharma , Paris, France Business: Cancer Appointed: Frederic Revah as CEO, former CSO of Cerep...
Items per page:
1 - 10 of 117
BioCentury | Jan 28, 2013
Company News

Cerep, Eurofins deal

...Eurofins began a tender offer to acquire Cerep for €2 per share, or about €25.3 million...
...deal was announced. Cerep's board unanimously approved the deal. The tender offer expires Feb. 27. Cerep...
...services for in vitro pharmacology, in vitro ADMET and in vivo pharmacokinetics for drug development. Cerep...
BioCentury | Apr 4, 2011
Finance

Eleventh Hour Push

...stabilizer in Phase III testing for Huntington's disease; expects to save $17.3M by 2012 1/18/11 Cerep...
BioCentury | Jan 24, 2011
Company News

Cerep admet, supply/service news

...company will close its office in Paris, France, and move its headquarters to Celle L'Evescault. Cerep...
...pharmacology, in vitro ADMET and in vivo pharmacokinetics for drug development. At June 30, 2010, Cerep...
...of €11.2 million ($13.7 million) and a six-month operating loss of €1.4 million ($1.7 million). Cerep...
BioCentury | Nov 1, 2010
Company News

Averion, Cerep deal

...to pay the interest on debt owed to Cerep stemming from Averion's 2007 acquisition of Cerep's...
...the debt are ongoing (see BioCentury, Nov. 5, 2007). Averion International Corp. (OTCBB:AVRO), Southborough, Mass. Cerep...
BioCentury | Jun 22, 2009
Company News

Cerep, Eli Lilly, Servier deal

...not disclosed. Separately, Cerep will screen Servier's compound library against targets identified by the pharma. Cerep...
...will be responsible for development and validation of pharmacological assays and profiling the compounds identified. Cerep...
...will receive an undisclosed monthly payment during the three-year deal. Further terms were not disclosed. Cerep...
BioCentury | Jan 12, 2009
Company News

Cerep, Laboratoires Thea deal

...exclusive, worldwide license to develop and commercialize Cerep's LFA-1 (CD11a-CD18) antagonist to treat ophthalmic disorders. Cerep...
...in animal models, which is expected to begin this half. The compound was discovered under Cerep's...
...to Cerep after hepatotoxicity was observed during Phase II testing for autoimmune and inflammatory diseases. Cerep...
BioCentury | Jan 8, 2009
Cover Story

Taking the inflammation out of epilepsy

...Inc. (NASDAQ:BIIB), Cambridge, Mass. BioInvent International AB (SSE:BINV), Lund, Sweden Biovitrum AB (SSE:BVT), Stockholm, Sweden Cerep...
...Corp. and Sunesis Pharmaceuticals Inc. , which have SAR1118 in Phase I testing for conjunctivitis. Cerep...
BioCentury | Dec 15, 2008
Company News

Cerep, sanofi-aventis deal

...payment to Cerep and reimbursement of certain Cerep's expenses. Cerep also is eligible for royalties. Cerep...
BioCentury | Jun 2, 2008
Finance

Next BioTech

...€199.3 Amsterdam Molecular (Euronext:AMT) €102.1 Bioalliance (Euronext:BIO) €88.1 Biotech (Pricaf) (Euronext:BIOT) €19.3 Cellectis (Euronext:ALCLS) €66.0 Cerep...
BioCentury | May 19, 2008
Company News

Sepal Pharma management update

...Sepal Pharma , Paris, France Business: Cancer Appointed: Frederic Revah as CEO, former CSO of Cerep...
Items per page:
1 - 10 of 117